Kirkland & Ellis LLP represented Pfizer Inc. in its definitive agreement announced today to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, including some countries in the European Union, and is expected to occur by the end of 2014.

The Kirkland team was led by corporate partners Jeffrey Symons, Dvir Oren and David Fox, and associate Willard Boothby and foreign associate Mattias Jonsson, with assistance from intellectual property partner David MacDonald, executive compensation partner Scott Price and tax partner Steven Clemens.